Follow-up and management of recurrent XXXX .

@entity1 @entity66 @entity242 @entity5606 @entity3969
Over the past 3 decades, enormous advances have been made in the creation of a standardized treatment protocol for @entity3969 . Less morbid regimens for low-risk @entity1 and more efficacious aggressive treatment protocols for high-risk @entity1 have been developed, and continue to be improved with newer studies, such as the NWTS-V. An area that has posed a more challenging aspect of the disease is its relapse. Although a standard follow-up protocol has been produced by in-depth evaluation of previous works, there has been a great deal of difficulty demonstrating improved relapse-free and overall survival rates in re-treatment of @entity1 suffering from recurrent @entity3969 . Several factors are involved in the success of treatment of relapse, some of which include prerelapse treatment of @entity66 and stage, site, and timing of recurrence. New agents and their combination with chemotherapeutics that already have established efficacy are being used for treatment of @entity3969 relapse, with varying success. These studies should lead the way for newer investigations in the future. @entity1 with @entity66 , @entity5606 , and clear cell @entity242 are especially in need of these future investigations. Perhaps the true final frontier is establishing the likelihood of @entity1 suffering a relapse. This topic currently is being studied in the fields of biologic markers and gene expression. This knowledge will hopefully, in turn, tailor initial treatment in a more specific manner.
